Thursday 16 October, 2025
Background: Most drugs do not exert their effect in plasma, where concentrations generally are measured, but in a defined target…
Read morePoster: Applications- Anti-infectives
Population pharmacokinetics of Ceftriaxone in intensive care unit (ICU) adult patients
Thursday 16 October, 2025
Objectives: Pharmacokinetics may be altered in severely ill patients. We describe population pharmacokinetics of ceftriaxone in a large group of…
Read moreModeling and Simulation of DEBIO-025 to Support Design of a Dose-Response Monotherapy Study in HIV-1 infected Patients
Thursday 16 October, 2025
PDF of poster Introduction: DEBIO-025 is a non-immunosuppressive cyclosporine with potent inhibitory activity on HIV replication in vitro due to…
Read morePopulation Pharmacokinetics of Ethambutol in South African Tuberculosis Patients
Thursday 16 October, 2025
Objectives: Ethambutol (EMB) is one of four drugs in the first-line antitubercular regimen and is used to protect against rifampicin…
Read moreParameter estimation of long-term HIV dynamic model in the COPHAR2 – ANRS 111 trial using MONOLIX
Thursday 16 October, 2025
Objectives: HIV dynamics studies, based on differential equations, have significantly improved the knowledge of HIV infection. While first studies use…
Read moreTherapeutic modelling and analysis of random feeding features of feed-administered chlortetracycline
Thursday 16 October, 2025
Objectives: In swine therapeutics, antibiotics are distributed mostly through feed offered for ad libitum consumption. The underlying assumption of collective…
Read morePopulation Pharmacokinetics of Atazanavir in HIV-infected Patients
Thursday 16 October, 2025
Objectives: The aim of the study was to determine the main pharmacokinetic (PK) parameters of ATV in real life using…
Read morePopulation Pharmacokinetics of Lopinavir (Kaletra) in HIV-Infected Patients
Thursday 16 October, 2025
Objectives: To develop and validate a population pharmacokinetic (PK) model of lopinavir (LPV) associated to ritonavir (RTV) (KaletraÒ) in HIV-infected…
Read morePopulation Pharmacokinetics of Efavirenz in HIV-infected patients: Pharmacogenetic analysis
Thursday 16 October, 2025
Objectives: Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, is often used in highly active antiretroviral therapy for the management of…
Read morePopulation pharmacokinetic model for Ritonavir (RTV) in HIV-infected patients treated with Lopinavir (LPV)/RTV (KaletraTM)
Thursday 16 October, 2025
Objectives: Having the population model previously obtained for LPV with the same data-set (Santos Buelga D. PAGE 2009), the aim…
Read more